Company news
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) news
Reviva Pharmaceuticals Holdings, Inc. news releases on 6ix. Latest, Sep 7, 2023: Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment…
Press releases — page 2
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 6, 2023
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
August 16, 2023
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 13, 2023
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
July 30, 2023
Reviva Pharmaceuticals to be Added to Russell Microcap® Index
June 25, 2023
Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
June 21, 2023
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June
June 14, 2023
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives
May 24, 2023
Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting
May 21, 2023
Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform
May 18, 2023
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023
May 17, 2023
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 14, 2023
Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
May 11, 2023
Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data
May 10, 2023
Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023
May 3, 2023
Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives
April 30, 2023
Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia
April 24, 2023
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
April 18, 2023
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights
March 29, 2023
Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference
March 6, 2023
Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference
January 30, 2023
Reviva Pharmaceuticals Announces Letter to Shareholders
January 3, 2023
Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
December 14, 2022
Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208
November 20, 2022
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 13, 2022
Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
October 30, 2022
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
October 12, 2022
Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference
September 25, 2022
Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
September 5, 2022
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 14, 2022
Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline
July 26, 2022
Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 15, 2022
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia
May 2, 2022
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights
March 14, 2022
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia
January 31, 2022
Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia
January 9, 2022
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 14, 2021
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights
August 15, 2021
Reviva Added to Russell Microcap® Index
June 27, 2021
Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering
May 25, 2021
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
April 25, 2021
Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update
March 21, 2021